GenePOC has received the CE marking for its third bacteriological test, GenePOC GBS DS, for the direct screening of Group B Streptococcus at intrapartum . Read the entire Press Release her.
GenePOC, has received the CE marking for its second bacteriological test, GenePOC CDiff, and for its centripetal sample-to-result instrument, called the revogene. Read the entire Press Release here.
GenePOC announces setup of an extensive network of commercial partners across Europe for distribution. GenePOC, which is ready to commercialize its first molecular solution for Clostridium difficile identification in Europe, is proud to announce that it has signed 8 distribution partners to cover the Western European market. Read more about it here.
GenePOC will attend the Association for Molecular Pathology’s (AMP) annual meeting, November 10-12, 2016 to be held at the Charlotte Convention Center, Charlotte – North Carolina.
As the leading event for Molecular Pathology and Molecular Diagnostics, it is the place where breakthrough innovations in clinical testing and patient care are introduced to the healthcare world.
GenePOC will be in Booth #1908. Come and join us – we will be pleased to meet you !
Read more about AMP 2016 here
GenePOC on GenomeWeb.
Debiopharm invests double-digit millions in GenePOC, specialized in the development of rapid diagnostic tests. GenePOC, which has just received CE marking for its first bacteriological test, will start commercialization in Europe this autumn, and Debiopharm will set up a future production line in Martigny. Click here for the details.
Click here to read the article.
GenePOC Recognized as the 2013 North American Molecular Diagnostics Entrepreneurial Company of the Year by Frost & Sullivan.
Contact UsIf you have questions, comments or need more information concerning GenePOC, talk to one of our customer service representatives. We will be pleased to assist you.
Write360 Rue Franquet, Porte 3
Canada G1P 4N3
Call1 (418) 650-3535
Monday to Friday
8:00 a.m. to 5:00 p.m. EST